Impaired activity of the fusogenic micropeptide Myomixer causes myopathy resembling Carey-Fineman-Ziter syndrome

Andres Ramirez-Martinez, …, Richard H. van Jaarsveld, Eric N. Olson

*J Clin Invest. 2022;132(11):e159002. https://doi.org/10.1172/JCI159002.*

Find the latest version:

https://jci.me/159002/pdf
Impaired activity of the fusogenic micropeptide Myomixer causes myopathy resembling Carey-Fineman-Ziter syndrome

Andres Ramirez-Martinez,1 Yichi Zhang,1 Marie-Jose van den Boogaard,2 John R. McAnally,1 Cristina Rodriguez-Caycedo,1 Andreas C. Chai,1 Francesco Chemello,1 Maarten P.G. Massink,2 Inge Cuppen,3 Martin G. Elferink,2 Robert J.J. van Es,4 Nard G. Janssen,4 Linda P.A.M. Walraven-van Oijen,2 Ning Liu,1 Rhonda Bassel-Duby,1 Richard H. van Jaarsveld,2 and Eric N. Olson1

1Department of Molecular Biology and Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2Department of Genetics, 3Department of Neurology, and 4Department of Oral and Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, Netherlands.

Skeletal muscle fibers contain hundreds of nuclei, which increase the overall transcriptional activity of the tissue and perform specialized functions. Multinucleation occurs through myoblast fusion, mediated by the muscle fusogens Myomaker (MYMK) and Myomixer (MYMX). We describe a human pedigree harboring a recessive truncating variant of the MYMX gene that eliminates an evolutionarily conserved extracellular hydrophobic domain of MYMX, thereby impairing fusogenic activity. Homozygosity of this human variant resulted in a spectrum of abnormalities that mimicked the clinical presentation of Carey-Fineman-Ziter syndrome (CFZS), caused by hypomorphic MYMK variants. Myoblasts generated from patient-derived induced pluripotent stem cells displayed defective fusion, and mice bearing the human MYMX variant died perinatally due to muscle abnormalities. In vitro assays showed that the human MYMX variant conferred minimal cell-cell fusogenicity, which could be restored with CRISPR/Cas9-mediated base editing, thus providing therapeutic potential for this disorder. Our findings identify MYMX as a recessive, monogenic human disease gene involved in CFZS, and provide new insights into the contribution of myoblast fusion to neuromuscular diseases.

Introduction

Cell-cell fusion is essential for numerous developmental events, including fertilization, placentation, and the formation of specialized cell types, such as osteoclasts and skeletal muscle fibers (reviewed in ref. 1). Intercellular fusion is a tightly regulated process, requiring recognition and merger of 2 or more cells to form a specialized multinucleated syncytium (2). As the largest tissue in the body, skeletal muscle undergoes extensive fusion during development as mononucleated myoblasts are recruited to nascent muscle fibers that ultimately expand to contain hundreds of nuclei (3). This process is essential for the establishment of the contractile apparatus and for motor innervation, allowing mobility.

Myoblast fusion involves a precisely coordinated series of events that include recognition between cells that are destined to fuse, followed by localization of fusogenic proteins to the sites of membrane mixing. We discovered 2 muscle-specific master regulators of myoblast fusion, Myomaker (4) (Mymk, also known as Tmem8c) and Myomixer (5–7) (Mymx, also known as Myomerg- er, Minion, or Gm7325), both of which are essential for muscle formation. MYMK is a 7-pass transmembrane protein that is required on both cells that are destined to fuse with each other (8), whereas MYMX is a single-pass transmembrane micropeptide that is required on only 1 of 2 fusing cells. When coexpressed in vitro, MYMX and MYMK are sufficient to promote fusion of cells that normally do not fuse, such as fibroblasts (5).

Fusogens juxtapose opposing membranes and expel the water between them, thus creating an energetically favorable environment for membrane merger, referred to as hemifusion, and the rapid opening of a fusion pore to mix cytosolic contents (9). Protein fusogens are typically characterized by long ectodomains capable of oligomerizing and reaching the opposing membrane upon conformational changes (10). Strikingly, MYMX is a small plasma membrane protein as short as 62 amino acids in some species (11). MYMX activity has been reported to be replaceable by osmotic shock in cell culture experiments (12), suggesting that MYMX may physically disrupt membrane integrity to drive fusion pore formation.

MyMx and MyMk are necessary for vertebrate skeletal muscle fusion in vivo, and mice lacking either of the 2 genes die at birth due to the lack of functional, multinucleated myofibers (4, 5). Similarly, deletion of Myomx or Myomk in adult satellite cells prevents skeletal muscle regeneration in response to injury (13, 14). These 2 fusogens are also conserved in zebrafish, where they are required for muscle formation (11, 15).

Whereas numerous muscle structural proteins have been associated with severe myopathies (16), relatively little is known about the potential contributions of the muscle fusion apparatus
to human disease. Recently, hypomorphic variants in MYMK were shown to cause the congenital myopathy known as Carey-Fine-Man-Ziter syndrome (CFZS; OMIM #254940) (17–20). CFZS patients display an array of abnormalities, including hypotonia, myofiber size disproportion, Moebius sequence, Pierre Robin complex, and growth defects (21). Fibroblasts expressing MYMK CFZS variants fail to fuse in vitro, but these mutations do not fully prevent muscle formation in vivo (20).

Here, we report that a single-nucleotide variant (SNV) in MYMX, which results in the loss of the conserved extracellular hydrophobic ectodomain, is associated with a CFZS-like phenotype in humans. Loss of the MYMX ectodomain generates a stable protein truncation with impaired fusogenic activity. Disease modeling with skeletal muscle cells generated from patient-derived induced pluripotent stem cells (iPSCs) revealed impaired myoblast fusion in vitro, and mice bearing the human MYMX mutation died neonatally due to defects in muscle formation. Our findings identify MYMX as a human disease gene and reveal new insights into the molecular basis of muscle formation.

Results

Identification of a MYMX variant in myopathic patients. Two individuals, a brother and a sister, presented in the clinic with a phenotype highly reminiscent of CFZS (22), a human disease caused by pathogenic variants in the MYMK gene (17–21). Diagnostic trio-exome sequencing of the affected patients did not identify any known pathogenic variants in myopathy-related genes, including MYMK. Open-exome analysis tailored toward the identification of recessive and/or de novo inherited variants revealed that both patients carried a homozygous C-to-T variant in codon 46 of MYMX on chromosome 6, resulting in conversion of Arg46 to a termination codon (NM_001315494.2 [MYMX]: c.136C>T [p.(Arg46*]) (Figure 1A). Both parents were heterozygous carriers of this SNV (Figure 1B), which was considered a strong candidate to explain the phenotypes, as (a) the variant was absent from control genomes (gnomAD database; ref. 23), (b) loss-of-function mutations of Mymx in mice phenocopy loss-of-function mutations in Mymk (4, 5), and (c) the patients’ phenotype closely resembled CFZS, associated with recessive variants in MYMK (20). Identity-by-descent analysis (24) revealed that the parents were related multiple generations back, possibly indicating a founder effect for this specific variant (Figure 1C).

The human and mouse MYMX proteins contain 84 amino acids that include an N-terminal transmembrane hydrophobic segment followed by a positively charged extracellular segment and a shorter hydrophobic segment with a conserved AxLyCxl motif that is required for myoblast fusion (Figure 1D and ref. 5). Mammalian MYMX proteins also contain a hydrophilic C-terminal segment that is absent from fish and turtle proteins. The premature stop codon at position 46 (referred to hereafter as R46*) results in loss of most of the hydrophobic extracellular ectodomain of MYMX, including the essential AxLyCxl motif (Figure 1E). Therefore, we considered MYMX R46* a promising novel candidate genetic variant involved in CFZS.

Clinical presentations of both patients included weakness of the facial musculature, hypomimic face, increased overbite, micrognathia, and facial dysmorphism (Figure 2A), while their parents were unaffected (Table 1). The female patient appeared more severely affected, presenting with failure to thrive, axial hypotonia, and progressive scoliosis (Figure 2B and clinical report in the supplemental material; supplemental material available online with this article; https://doi.org/10.1172/JCI159002DS1). Prior studies showed fiber type disproportion and myopathy in quadriceps muscles from CFZS patients (20). However, a muscle biopsy taken from the trunk muscle (musculus longissimus dorsi) of the female patient showed minimal pathology (Figure 2C), probably reflecting differences across muscle groups. A muscle biopsy from the male patient was not available. Overall, these findings suggested that compromised MYMX activity could potentially cause muscle abnormalities resembling those of CFZS patients, who harbor hypomorphic MYMX variants.

The MYMX R46* variant prevents fusion of myoblasts from patient-derived iPSCs. To assess muscle abnormalities in vivo, skeletal muscle cells were differentiated from iPSCs derived from gingival fibroblasts from the male patient (Figure 3A). To precisely determine the contribution of the MYMX R46* variant to the human phenotype and eliminate the influence of other genetic variants present in the patient, we generated an isogenic control cell line by genetically editing the MYMX R46* allele to MYMX WT sequence. To revert the c.136C>T SNV in MYMX R46*, we used CRISPR/Cas9–mediated adenine base editing, which converts A:T genomic base pairs into G:C base pairs (25). Specifically, to generate isogenic control cells, homozygous MYMX R46* iPSCs were nucleofected with plasmids encoding the adenine base editor NG-ABEmax (26) and an sgRNA targeting the R46* locus (Figure 3B). Sanger sequencing of nucleofected iPSCs showed an editing efficiency of 84% of the targeted nucleotide (T12) in sorted cells with minimal bystander editing of nucleotide T10 (Figure 3C). Patient-derived, isogenic, single iPSC clones homozygous for MYMX R46* or for MYMX WT (edited) were used for subsequent studies.

Cell lines were differentiated into skeletal muscle by defined chemical factors (27), and myoblast fusion was examined. Whereas the MYMX WT (edited) isogenic control muscle cells readily formed long multinucleated myotubes, fusion of homozygous MYMX R46* muscle cells was severely impaired (Figure 3D). Reduced multinucleation was not caused by a failure to differentiate, as cells were positive for the myosin heavy chain muscle marker My32, as detected by immunostaining (Figure 3D). Notably, quantitative reverse transcription PCR (qRT-PCR) analysis revealed that while MYOD1 transcript levels were slightly downregulated in MYMX R46* myotubes, the myogenic regulator MYOG, the differentiation marker DES, and the muscle fusogens MYMK and MYMX were expressed at equivalent levels in MYMX R46* myotubes, despite their inability to fuse (Figure 3E).

MYMX R46* mice recapitulate a lethal CFZS-like phenotype. To model the muscle abnormalities associated with the MYMX R46* variant, we genetically engineered mice with this mutation by CRISPR/Cas9–mediated genome editing. The c.136C>T variant within codon 46 was introduced, together with 2 additional silent mutations, such that the surrounding genomic sequences were identical between human and mouse (Figure 4A). Heterozygous MYMX R46* mice showed no obvious abnormalities compared with WT mice. Homozygous MYMX R46*/R46* mice were born at the expected Mendelian ratios from heterozygous intercrosses.
that died at birth (Figure 5B), suggesting a hypomorphic fusion phenotype. Muscles from Mymx R46*/R46* mice also displayed fiber size disproportion (Figure 5C). Ultrastructural analysis of Mymx R46*/R46* hind-limb muscles by electron microscopy showed fragmented sarcomeres and evidence of myofiber degeneration (Figure 5D). Thus, the homozygous Mymx R46*/R46* mice recapitulated a myopathic phenotype reminiscent of that of CFZS patients.

**MYMX R46* is a stable hypomorphic protein with minimal fusogenicity.** To understand the mechanistic basis of fusion abnormalities of the MYMX R46* variant, we generated retroviral constructs encoding full-length human MYMX WT or MYMX R46*. These constructs were functionally characterized in vitro with heterologous fusion assays (28), using a split luciferase system in which luciferase activity can be reconstituted by interaction of the N- and C-terminal domains of luciferase, referred to as RLuc1 and RLuc2, respectively (Figure 6A). For these assays, C2C12 myoblasts expressing mCherry-RLuc1 were mixed with 10T1/2 fibroblasts expressing GFP-RLuc2, and myoblast differentiation...
to MYMX WT. However, truncation of the MYMX ectodomain diminishes its functional activity, impairing muscle fusion and causing a hypomorphic phenotype with developmental abnormalities associated with CFZS.

Discussion

Myoblast fusion is essential for muscle development and postnatal muscle function (29). Here we show the involvement of MYMX, an essential muscle fusogen, in the etiology of CFZS, a progressive congenital myopathy with developmental defects (21). We identified 2 siblings presenting with CFZS clinical manifestations and revealed by trio-exome sequencing that they harbor a homozygous MYMX R46* variant. Prior studies on CFZS patients identified pathogenic gene variants in MYMK, another essential muscle fusogen, that caused protein instability and impaired muscle fusion (20). Further identification of other MYMX variants will help to decipher how muscle fusogens contribute to the pathology of CFZS and reconcile the diversity of histological phenotypes among patients. Overall, these studies indicate that defects in the master regulators of muscle fusion directly contribute to neuromuscular disorders, such as CFZS.

MYMX R46* is a truncated variant missing part of its extracellular region (ectodomain). Disease modeling of MYMX R46* using patient-derived iPSCs revealed defects in myoblast fusion, and in vitro fusion assays showed that the fusogenic activity of the MYMX R46* protein is severely compromised. The MYMX R46* protein is stable and shows no obvious abnormalities in localization. These results highlight the importance of the ectodomain of MYMX for myoblast fusion. It will be important to elucidate the precise molecular mechanism whereby this short domain drives cell fusion. Intriguingly, evolutionary analysis of MYMX orthologs revealed that the only region strictly conserved across species is the extracellular AxLyCxL motif (11), which is lost in the MYMX R46* truncation. In addition, the ectodomain of MYMX contains a stretch of basic residues that may interact with other charged molecules at the plasma membrane to promote fusion, and disruption of the MYMX ectodomain by combined point mutations is sufficient to abolish its fusogenic activity (5). Our data indicate that the MYMX R46* truncation is a pathogenic, hypomorphic variant, associated with impaired myoblast fusion that resembles the clinical manifestation of CFZS.

Mymx R46*/R46* mice represent a new mouse model for the human disorder, CFZS, caused directly by an impairment in myoblast fusion. Mymx R46*/R46* mice died shortly after birth, and histological analysis showed compromised myoblast fusion, whereas CFZS is not lethal in humans. The initial study was induced. Myoblast-fibroblast fusion was then assessed by quantification of GFP’mCherry’ chimeric myofibers and measurement of reconstituted luciferase activity. In the presence of MYMK, MYMX WT strongly enhanced heterologous fusion, whereas the MYMX R46* variant had minimal fusogenicity (Figure 6, B and C). We then used C-terminally myc-tagged MYMX constructs to assess protein stability and localization. Western blot analysis (Figure 6D) and immunofluorescence of myc-tagged MYMX proteins (Figure 6E) revealed that MYMX WT and MYMX R46* constructs were expressed at equivalent levels and displayed comparable localization. These findings indicate that the MYMX R46* variant, observed in the CFZS-like patients, generates a stable truncated protein with similar localization to MYMX WT.
Table 1. Clinical findings in MYMX R46*/R46* patients

| Individual | Case 1 | Case 2 |
|------------|--------|--------|
| Sex        | F      | M      |
| Age at last examination (yr) | 14     | 11     |
| Descent    | Dutch  | Dutch  |
| Height (cm) | 152.7 (–1.75 SD) | 147.5 (–0.2 SD) |
| Weight (kg) | 30.6 (–3.45 SD) | 32.5 (–0.63 SD) |
| Head circumference (cm) | 51 (–1.9 SD) (13 yr) | 53 (–0.1 SD) (10 yr) |
| Failure to thrive (HP:0001508) | +      | –      |
| Nasal speech (HP:0001681) | –      | +      |
| Phenotype |
| Weakness of facial musculature (HP:0030319) | +      | +      |
| Axial muscle weakness (HP:0003327) | +      | –      |
| Hypomimic face (HP:0000338) | +      | –      |
| Hooded upper eyelid (HP:0030822) | +      | +      |
| Underdeveloped nasal alae (HP:0000430) | +      | +      |
| Anteverted nares (HP:0000463) | –      | +      |
| Abnormality of the nasal septum (HP:0000419) | +      | –      |
| Long philtrum (HP:0000343) | +      | –      |
| Increased overbite (HP:0011094) | +      | –      |
| Downturned corners of mouth (HP:0002714) | +      | –      |
| Thin upper lip vermilion (HP:0000219) | +      | –      |
| High, narrow palate (HP:0002705) | +      | –      |
| Dental crowding (HP:0000411) | –      | +      |
| Muscle weakness (L/R) (1 to 5) |
| Neck flexors (MRC) | 5/5 | 5/5 |
| Anteflexion 4/4 | Anteflexion 4/4 |
| Biceps 5/5 | Abduction 4/4 |
| Triceps 5/5 | Biceps 4–5/4–5 |
| Wrist extension/flexion 5/5 | Triceps 4–5/4–5 |
| Hands |
| Flexion 5/5 | Flexion 4–5/4–5 |
| Extension 5/5 | Extension 4–5 |
| Proximal lower extremities (MRC) |
| Iliopsoas 4/4 | Iliopsoas 4/4 |
| Gluteus medius 4/4 | Quadriceps femoris 4–5/4–5 |
| Hamstrings 4/4 | Hip adductors 4/4 |
| Distal lower extremities (MRC) |
| Feet, extension 4/4 | Feet, extension 4/4 |
| Feet, flexion 5/5 | Feet, flexion 5/5 |
| Invertors 4/4 | Invertors 4–5/4–5 |
| Evertors 4/4 | Evertors 4/4 |
| Reflexes |
| Symmetrical, 1+ | 1+, Patellar R>L, Plantar: plantar flexion |

Overview of the most prominent clinical findings in both siblings. Phenotypes according to Human Phenotype Ontology HP codes (https://doi.org/10.1093/nar/gkaa1043). MRC, Medical Research Council muscle strength score.

that identified pathogenic MYMK variants associated with CFZS also included in vivo experiments in zebrafish (20) and reported that delivery of mRNAs encoding MYMK CFZS variants failed to rescue the mymk-null zebrafish model. Instead, those animals presented myopathic features. However, in contrast to Mymk-KO mice, mymk-null zebrafish are viable (30, 31). These phenotypic differences highlight the variability in myoblast fusion across species. For instance, in humans and mice, all muscle fibers undergo fusion, whereas in zebrafish, myoblast fusion only occurs in fast-twitch fibers (32). In vitro studies have shown that mouse Mymk-KO myoblasts cannot fuse, whereas in human MYMK-KO myoblasts, MYMK is sufficient to induce low levels of fusion (33). We hypothesize that additional genes may compensate for impaired MYMX function in humans, but not in mice. With the identification of MYMK and MYMX as muscle fusogens, evolutionary studies on myoblast fusion are necessary to further understand these differences.

The widespread role of cell-cell fusion in human disease has become increasingly appreciated. Defects in cell-cell fusion are involved in infertility (34), preeclampsia (35), osteoporosis (36), cancer (37), and infection (10, 38). In skeletal muscle, alterations in myoblast fusion have been reported to contribute to the pathology of human neuromuscular diseases (39, 40) such as Duchenne muscular dystrophy (41, 42), limb-girdle muscular dystrophy (43), and Emery-Dreifuss muscular dystrophy (44). The discovery of pathogenic variants in MYMK and MYMX highlights a new form of fusogenic myopathy. Myoblast fusion is required to increase the transcriptional diversity and capacity of skeletal muscle (45–48), and impairment of myoblast fusion below a certain threshold cannot be compensated by the remaining nuclei (42, 49, 50). It will be clinically important to determine whether genetic variants in other components of the fusion machinery cause similar human disorders.

Currently, there is no cure for CFZS. Gene therapy has been used successfully in clinical trials to treat genetic neuromuscular disorders such as spinal muscular atrophy (51, 52). However, MYMX expression is strictly restricted to myoblast fusion (5), and studies in mice suggest that overexpression of muscle fusogens could negatively impact muscle fiber integrity in dystrophic conditions (42). Recently, CRISPR/Cas9 base editing has emerged as an attractive therapeutic genome editing tool to directly correct disease-causing mutations and maintain endogenous expression levels of the corrected genes (53). Several studies have shown that in vivo delivery of base editors by adeno-associated viruses can target specific tissues, edit target genes, restore gene function, and

J Clin Invest. 2022;132(11):e159002 https://doi.org/10.1172/JCI159002
ameliorate a broad spectrum of pathologies, including muscular dystrophies, metabolic disorders, and hereditary blindness (53). Using patient-derived iPSC myotubes, we show that the \textit{MYMX} \textit{R46}* variant is amenable to therapeutic correction by base editing. Further work with \textit{Mymx}\textit{R46*/R46*} mice and other humanized CFZS mouse models needs to be done to assess whether base editing can improve muscle pathology in vivo, and thus pave the way for a future treatment for this disorder.

\textbf{Methods}

\textbf{Human genetic analyses.} The \textit{MYMX} genetic variant was detected through clinical whole-exome sequencing (WES) performed at the University Medical Center Utrecht Genetics department according to local standardized diagnostic procedures. WES was performed using an Illumina NovaSeq 6000 platform on exome-enriched samples (Agilent Sureselect CREv2) from DNA isolated from peripheral blood. Diagnostic variant filtering based on the American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines (54) was performed using Agilent Alissa Interpret software. TRIBES software (v0.2.0) was used to estimate the degree of relatedness between samples (24). Analysis was performed on WES data from all family members and 7 randomly selected, unrelated in-house control samples. If no estimated degree of relatedness was detected, relatedness was manually set to 12.

\textbf{Generation of patient iPSC-derived skeletal muscle cells.} Gingival fibroblasts isolated from a \textit{MYMX}\textit{R46*/R46*} patient were reprogrammed into iPSCs with Sendai virus (Thermo Fisher Scientific, A16517) per the manufacturer’s instructions. Patient-derived iPSCs were maintained in mTeSR Plus medium (Stemcell Technologies, 100-0276) and plated on Matrigel-coated plates. iPSCs were dissociated with Accutase (Innovative Cell Technologies, AT104) and nucleofected with P3 Primary Cell 4D-Nucleofector X Kit (Lonza) per the manufacturer’s instructions. The plasmids used for nucleofection were \textit{NG-ABEmax} (26) (Addgene, 124163) and \textit{pmCherry_gRNA} (Addgene, 80457). The following sgRNA sequence was cloned into \textit{pmCherry_gRNA} and used for base editing of the human \textit{MYMX} locus: \textit{hs.MYMX.sgRNA}: 5′-AGCCTCTCGCATGTCCTGGG-3′.
Forty-eight hours after nucleofection, mCherry-positive cells were isolated by FACS. The overall efficiency of base editing was assessed by isolation of genomic DNA from mCherry-positive cells, Sanger sequencing, and EditR analysis (55). Additionally, mCherry-positive single clones were isolated for genotyping and further studies. The following primers were used for PCR amplification with Taq polymerase (New England Biolabs, M0273): hs.MYMX.geno-F: 5′-GTGAGGCAGAACCAGGACAT-3′; hs.MYMX.geno-R: 5′-AACCTCTCCCTCCTCTCCAG-3′.

iPSCs were differentiated into skeletal muscle cells by defined factors as previously described (27). Briefly, the method recapitulates muscle development by the stepwise differentiation of iPSCs into paraxial mesoderm, myogenic progenitors, and, finally, muscle fibers.

**Immunofluorescence.** Cells were fixed for 10 minutes in 4% paraformaldehyde, permeabilized for 30 minutes in 5% BSA in PBS. The following antibodies were diluted in blocking solution at 1:200 dilution and added to cells for 1 hour: My32 (MilliporeSigma, M4276) and myc (Thermo Fisher Scientific, R950-25). Hoechst 33342 (Thermo Fisher Scientific, H3570) was used to label nuclei.

**Generation of Mymx R46* mice.** To generate humanized Mymx R46* mice, Cas9 nickase D10A was used (56). The sgRNAs used for injection were: mm.Mymx.sgRNA-5′: 5′-CAGACTCTGGAGCCCTCTCCAGAATCCGGTGGCTGTTGCTG-GCTGAGGACAAAGAGCAGACAGCTCAGCAAAGCCTCTCATGTCGTGGAGCTTAGCTGACGCGCCGCAC-3′; mm.Mymx.sgRNA-3′: 5′-CCACTCCTCGCTCTCCGGGAGCTCAGTCGGCGGGGCAGCCGGGAC-3′.

Cas9 nickase D10A mRNA, sgRNAs, and ssODN were injected into the pronucleus of zygotes and transferred into the oviducts of pseudopregnant ICR female mice. F0 mice were genotyped by Sanger sequencing after genomic DNA isolation by phenol-chloroform purification. Taq polymerase (New England Biolabs, M0273) and the following primers were used for PCR amplification: mm.Mymx.geno-F: 5′-GCGTGCCTGAGGTACAGTCT-3′; mm.Mymx.geno-R: 5′-GTCA-GAGCCCTCTCAGCTCAGGAGCAGGCC-3′.

F0 mosaic mice were mated to C57BL/6N mice, and the progeny were genotyped to establish a mouse colony.

**Histological analysis.** Skeletal muscles and lungs were fixed for 16 hours at 4°C in 4% paraformaldehyde, and routine paraffin embedding and H&E staining were performed. For immunofluorescence, antigen retrieval was performed with SignalStain Citrate Unmasking Solution (Cell Signaling Technology, 14746) per the provider’s instructions. Sections were then permeabilized in 0.3% Triton X-100 for 15 minutes and blocked with mouse-on-mouse blocking solution (Vector Laboratories, B4105) and 5% goat serum. The following antibodies were used at 1:200 dilution: ACTA1 (Proteintech, 17521-1-AP), wheat germ agglutinin and Alexa Fluor 647 conjugate (Thermo Fisher Scientific, W32466), and anti-rabbit Alexa Fluor 555 secondary...
RNA from iPSC-derived skeletal muscle cells was solubilized in 1 mL of TRIzol (Thermo Fisher Scientific, 15596026), and cDNA was generated with iScript Reverse Transcriptase (Bio-Rad, 1725035). The following primers were used for qRT-PCR (33): hs.qPCR.MYOD1-F: 5′-CGACGGCATGATGGACTACA-3′; hs.qPCR.MYOD1-R: 5′-TATATCGGGTTGGGGTTCGC-3′; hs.qPCR.MYOG-F: 5′-GGGGAAAACTACCTGCCTGTC-3′; hs.qPCR.MYOG-R: 5′-AGGCGCTCGATGTACTGGAT-3′; hs.qPCR.MYMX-F: 5′-CTGATTCTGAGCAGCAGTTCT-3′; hs.qPCR.MYMX-R: 5′-AATGAACAGCAGACAGCCCA-3′; hs.qPCR.MYMK-F: 5′-TGTGCGGATCTACCATGACC-3′; hs.qPCR.MYMK-R: 5′-GACGCTCTTGTCTGGGTACAG-3′.

Western blot analysis. Protein was isolated from cell pellets by solubilization in 1 mL of TRIzol (Thermo Fisher Scientific, 15596026), and cDNA was generated with iScript Reverse Transcriptionase (Bio-Rad, 1725035). The following primers were used for qRT-PCR (33): hs.qPCR.MYOD1-F: 5′-CGACGGCATGATGGACTACA-3′; hs.qPCR.MYOD1-R: 5′-TATATCGGGTTGGGGTTCGC-3′; hs.qPCR.MYOG-F: 5′-GGGGAAAAACTACCTGCCTGTC-3′; hs.qPCR.MYOG-R: 5′-AGGCGCTCGATGTACTGGAT-3′; hs.qPCR.MYMX-F: 5′-CTGATTCTGAGCAGCAGTTCT-3′; hs.qPCR.MYMX-R: 5′-AATGAACAGCAGACAGCCCA-3′; hs.qPCR.MYMK-F: 5′-TGTGCGGATCTACCATGACC-3′; hs.qPCR.MYMK-R: 5′-GACGCTCTTGTCTGGGTACAG-3′.

Electron microscopy. Skeletal muscles from neonatal mice were flash-frozen and homogenized in 1 mL of TRIzol (Thermo Fisher Scientific, 15596026). Three mice per genotype were used. RNA isolation and RNA sequencing library preparation were performed with Quick-RNA Miniprep Plus Kit (Zymo Research, R1057) and KAPA mRNA HyperPrep kit (Kapa Biosystems, KK8580) per the providers’ instructions. RNA sequencing was performed by the CRI Sequencing Facility at the University of Texas Southwestern Medical Center. Bioinformatics analysis was performed as previously described (57). Low-quality reads were excluded (with fewer than 30% nucleotides with Phred quality scores below 20), and the remaining reads were aligned to the mouse genome (GRCm38.mrn10) with HISAT2 aligner (v2.1.0) and counted with featureCounts (v1.6.2). DESeq2 R Bioconductor was used to obtain the differentially expressed genes between groups.
myoblast differentiation. DMEM without phenol red (Thermo Fisher Scientific, 21063029) was used in 96-well plates, as phenol red reduced luciferase signal.

Five days after differentiation, cells in 12-well plates were fixed in 4% paraformaldehyde in PBS, permeabilized in 0.3% Triton X-100 for 15 minutes, and stained with Hoechst 33342 (Thermo Fisher Scientific, H3570). Cells in 96-well plates were used for luciferase assays. A cell-permeable firefly luciferase substrate, ViviRen (Promega, E6491), was used per the provider’s instructions. CLARIOstar plate reader (BMG Labtech) was used for luminescence readings.

Statistics. Statistical comparisons between groups were evaluated by unpaired and 2-sided Student’s t test. For multiple comparisons, 1-way ANOVA was used. A P value lower than 0.05 was considered statistically significant.

Study approval. For human genetic studies, informed consent forms for the publication of clinical and genetic data were signed by the parents and made part of the digital health care records at the University Medical Center Utrecht. All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center.
Author contributions
ARM, YZ, NL, RBD, RHJV, and ENO wrote and edited the manuscript. RHJV supervised clinical research and performed project administration and conceptualization. MJVDB, IC, RJVE, and NGJ performed clinical assessment and data collection. ARM, YZ, and ENO designed the experiments and analyzed the data. FC and ACC designed base editing experiments. ARM, YZ, and CRC performed the experiments. JRM performed the zygote injections to generate Mymx R46* mutant mice. MPGM and RHJV performed human genetic analysis. MGE and LWVO performed identity-by-descent analysis.

Acknowledgments
We thank J. Cabrera for graphics, and L. Guo and L. Xi for bioinformatics analysis. We thank our colleagues M.C. Kruijt, S.G. Kant, E.H. Niks, and W. van Hecke for expert advice. We thank G.A. Garry for expert clinical advice. We thank the following Core Facilities at the University of Texas Southwestern Medical Center: the Molecular Pathology Core under the direction of B. Evers, the Electron Microscopy Core under the direction of K. Luby-Phelps, and the Children’s Medical Center Research Sequencing facility under the direction of J. Xu. We thank the following facilities at the University Medical Center Utrecht: Bioinformatics under the supervision of H. van Deutekom and Genome Diagnostics under the direction of H.K. Ploos van Amstel. This work was supported by grants from the NIH (HL130253 and HD087351) and the Robert A. Welch Foundation (1-0025) to ENO.

Address correspondence to: Eric N. Olson, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. Phone: 214.648.1187; Email: Eric.Olson@utsouthwestern.edu. Or to: Richard H. van Jaarsveld, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, Netherlands. Phone: 31.0.88.75.538.00; Email: r.h.vanjaarsveld@umcutrecht.nl.
42. Petrany MJ, et al. Myocyte-derived Myomaker expression is required for regenerative fusion but exacerbates membrane instability in dystrophic myofibers. *JCI Insight*. 2020;5(9):e136095.

43. Cohen TV, et al. Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response. *Neuromuscular Disord*. 2012;22(7):648–658.

44. Gnocchi VF, et al. Uncoordinated transcription and compromised muscle function in the *lmna*-null mouse model of Emery-Dreifuss muscular dystrophy. *PLoS One*. 2011;6(2):e16651.

45. Dos Santos M, et al. Single-nucleus RNA-seq and FISH identify coordinated transcriptional activity in mammalian myofibers. *Nat Commun*. 2020;11(1):5102.

46. Petrany MJ, et al. Single-nucleus RNA-seq identifies transcriptional heterogeneity in multinucleated skeletal myofibers. *Nat Commun*. 2020;11(1):6374.

47. Kim M, et al. Single-nucleus transcriptomics reveals functional compartmentalization in syncytial skeletal muscle cells. *Nat Commun*. 2020;11(1):6375.

48. Chernello F, et al. Degenerative and regenerative pathways underlying Duchenne muscular dystrophy revealed by single-nucleus RNA sequencing. *Proc Natl Acad Sci U S A*. 2020;117(47):29691–29701.

49. Cramer AAW, et al. Nuclear numbers in syncytial muscle fibers promote size but limit the development of larger myonuclear domains. *Nat Commun*. 2020;11(1):6287.

50. Goh Q, Millay DP. Requirement of myomaker-mediated stem cell fusion for skeletal muscle hypertrophy. *Elife*. 2017;6:e20007.

51. Al-Zaidy S, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatr Pulmonol*. 2019;54(2):179–185.

52. Mendell JR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *N Engl J Med*. 2017;377(18):1713–1722.

53. Lim JM, Kim HH. Basic principles and clinical applications of CRISPR-based genome editing. *Yonsei Med J*. 2022;63(2):105–113.

54. Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405–424.

55. Kluesner MG, et al. EditR: a method to quantify base editing from sanger sequencing. *CRISPR J*. 2018;1:239–250.

56. Ran FA, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell*. 2013;154(6):1380–1389.

57. Ramirez-Martinez A, et al. The nuclear envelope protein Net39 is essential for muscle nuclear integrity and chromatin organization. *Nat Commun*. 2021;12(1):690.